CA3122108A1 - Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors - Google Patents

Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors Download PDF

Info

Publication number
CA3122108A1
CA3122108A1 CA3122108A CA3122108A CA3122108A1 CA 3122108 A1 CA3122108 A1 CA 3122108A1 CA 3122108 A CA3122108 A CA 3122108A CA 3122108 A CA3122108 A CA 3122108A CA 3122108 A1 CA3122108 A1 CA 3122108A1
Authority
CA
Canada
Prior art keywords
optionally substituted
cancer
alkyl
pyrazolo
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3122108A
Other languages
English (en)
French (fr)
Inventor
Jehrod Burnett BRENNEMAN
Elsa Beyer KRALL
Michael Schlabach
Andrew Alistair WYLIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KSQ Therapeutics Inc
Original Assignee
KSQ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KSQ Therapeutics Inc filed Critical KSQ Therapeutics Inc
Publication of CA3122108A1 publication Critical patent/CA3122108A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3122108A 2018-12-20 2019-12-19 Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors Pending CA3122108A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862783014P 2018-12-20 2018-12-20
US62/783,014 2018-12-20
US201962799423P 2019-01-31 2019-01-31
US62/799,423 2019-01-31
US201962857986P 2019-06-06 2019-06-06
US62/857,986 2019-06-06
US201962868616P 2019-06-28 2019-06-28
US62/868,616 2019-06-28
US201962946263P 2019-12-10 2019-12-10
US62/946,263 2019-12-10
PCT/US2019/067521 WO2020132269A1 (en) 2018-12-20 2019-12-19 Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors

Publications (1)

Publication Number Publication Date
CA3122108A1 true CA3122108A1 (en) 2020-06-25

Family

ID=71100912

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3122108A Pending CA3122108A1 (en) 2018-12-20 2019-12-19 Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors

Country Status (16)

Country Link
US (2) US11485736B2 (https=)
EP (1) EP3897652A4 (https=)
JP (2) JP7662519B2 (https=)
KR (1) KR102912147B1 (https=)
CN (1) CN113164485A (https=)
AU (1) AU2019405925B2 (https=)
BR (1) BR112021010715A2 (https=)
CA (1) CA3122108A1 (https=)
CL (1) CL2021001575A1 (https=)
CO (1) CO2021009078A2 (https=)
IL (1) IL284050B2 (https=)
MX (1) MX2021007179A (https=)
PH (1) PH12021551402A1 (https=)
SG (1) SG11202106232TA (https=)
TW (2) TWI895986B (https=)
WO (1) WO2020132269A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189841B2 (en) 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
BR112021010715A2 (pt) 2018-12-20 2021-11-16 Ksq Therapeutics Inc Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
JP7253640B2 (ja) 2019-01-31 2023-04-06 武田薬品工業株式会社 複素環化合物およびその用途
ES3025474T3 (en) * 2020-01-15 2025-06-09 Ksq Therapeutics Inc Compositions of substituted pyrazolopyrimidines and uses thereof
CA3168009A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
EP4161494A4 (en) * 2020-06-02 2024-07-17 KSQ Therapeutics, Inc. NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
WO2022053998A1 (en) * 2020-09-10 2022-03-17 Universidade Do Porto New pharmaceutical compounds, methods and uses thereof
KR20230098186A (ko) * 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
US20240182481A1 (en) * 2021-02-15 2024-06-06 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
AU2022238886A1 (en) * 2021-03-17 2023-09-14 Medivir Ab Purine derivatives as anticancer agents
MX2023011709A (es) * 2021-04-07 2023-10-12 Forma Therapeutics Inc Inhibidor de la proteasa 1 especifica de ubiquitina (usp1).
CN117337290B (zh) * 2021-05-03 2026-01-02 轩竹生物科技股份有限公司 三并环类泛素特异性蛋白酶1抑制剂及其用途
WO2022253188A1 (en) * 2021-05-31 2022-12-08 Impact Therapeutics (Shanghai) , Inc Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof
GB202114863D0 (en) 2021-10-18 2021-12-01 Syngenta Crop Protection Ag Improvements in or relating to organic compounds
JP2024540921A (ja) * 2021-10-19 2024-11-06 上海瑛派▲薬▼▲業▼有限公司 Ｕｓｐ１阻害剤としての置換トリアゾロヘテロアリール化合物及びその応用
CN114031556B (zh) * 2021-11-08 2023-03-31 温州大学 一种绿色的一锅法制备5-氨基-n-芳基-3-芳基吡唑类化合物的合成方法
GEAP202416531A (en) * 2021-11-12 2024-10-28 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
CR20240191A (es) * 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
EP4430041A4 (en) * 2021-11-12 2025-09-24 Insilico Medicine Ip Ltd SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES
CN114181237B (zh) * 2021-12-01 2024-02-23 上海凌凯医药科技有限公司 一种1-异丙基吡唑-5-硼酸频那醇酯的合成方法
IL312982A (en) * 2021-12-09 2024-07-01 Ksq Therapeutics Inc Methods for the preparation of converted pyrazolopyrimidines
CN118525022A (zh) * 2022-01-27 2024-08-20 西藏海思科制药有限公司 一种氮杂并环衍生物及其在医药上的应用
US20250163049A1 (en) * 2022-02-03 2025-05-22 Exelixis, Inc. Fused bicyclic heterocyclyl compounds as usp1 inhibitors
US20250382289A1 (en) * 2022-02-18 2025-12-18 Xizang Haisco Pharmaceutical Co., Ltd. Pyrazolopyridine derivative and application thereof in medicine
IL315748A (en) * 2022-04-08 2024-11-01 Ksq Therapeutics Inc Therapeutic combinations containing ubiquitin-specific processing protease 1 (USP1) inhibitors and chemotherapy agents
CN116925098B (zh) * 2022-04-09 2026-02-17 深圳湾实验室 靶向泛素特异性蛋白酶1(usp1)的小分子抑制剂及其应用
AU2023261809A1 (en) * 2022-04-29 2024-12-05 Asieris Pharmaceuticals (Shanghai) Co., Ltd. Pyrimidine compound, method for preparing same, and pharmaceutical use thereof
EP4543890A1 (en) * 2022-06-23 2025-04-30 Forma Therapeutics, Inc. Usp1 inhibitors and uses thereof
WO2024006879A1 (en) * 2022-06-29 2024-01-04 Zentaur Therapeutics Usa Inc. Usp1 inhibitors and uses thereof
WO2024022266A1 (en) * 2022-07-25 2024-02-01 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heteroaryl compounds as inhibitors of usp1
WO2024022519A1 (zh) * 2022-07-28 2024-02-01 先声再明医药有限公司 杂环并嘧啶类化合物及其应用
CN119522224A (zh) * 2022-08-09 2025-02-25 上海济煜医药科技有限公司 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
CN117263944B (zh) * 2022-08-24 2025-10-17 轩竹生物科技股份有限公司 泛素特异性蛋白酶1抑制剂及其用途
CN119790043A (zh) * 2022-08-26 2025-04-08 海南先声再明医药股份有限公司 三环类化合物及其应用
US20250368667A1 (en) * 2022-09-02 2025-12-04 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Usp1 inhibitor
TW202411231A (zh) * 2022-09-09 2024-03-16 大陸商正大天晴藥業集團股份有限公司 用作泛素-特異性蛋白酶抑制劑的取代嘌呤酮衍生物
IL319492A (en) * 2022-09-20 2025-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A carbonyl-fused heterocyclic derivative that acts as a ubiquitin-specific protease
CN117384187B (zh) * 2022-09-30 2026-01-30 轩竹生物科技股份有限公司 泛素特异性蛋白酶1抑制剂
WO2024078436A1 (zh) * 2022-10-09 2024-04-18 海南先声再明医药股份有限公司 杂环并嘧啶类化合物、药物组合物及其应用
WO2024086790A1 (en) 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
WO2024094170A1 (zh) * 2022-11-04 2024-05-10 深圳晶泰科技有限公司 泛素特异性蛋白酶1的抑制剂及其应用
CN120513237A (zh) 2023-01-12 2025-08-19 先正达农作物保护股份公司 除草咪唑化合物
CN120603835A (zh) * 2023-01-20 2025-09-05 杭州英创医药科技有限公司 作为usp1抑制剂的化合物
WO2024222880A1 (zh) * 2023-04-27 2024-10-31 西藏海思科制药有限公司 一种吡啶并吡唑衍生物的药物组合物及其在医药上的应用
WO2024233605A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
CN116768906B (zh) * 2023-05-29 2024-04-09 遵义医科大学珠海校区 一种三并环化合物及其制备方法和应用
CN121511238A (zh) * 2023-07-05 2026-02-10 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
CN121219283A (zh) * 2023-07-05 2025-12-26 江苏亚虹医药科技股份有限公司 联嘧啶化合物的晶型及其制备方法和用途
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
WO2025015905A1 (en) * 2023-07-14 2025-01-23 Laekna Therapeutics Shanghai Co., Ltd. Pyrimidine compounds and their use as usp1 inhibitors
TW202530229A (zh) * 2023-09-26 2025-08-01 大陸商上海濟煜醫藥科技有限公司 氮雜環胺類化合物作為泛素-特異性蛋白酶１抑制劑的製備方法、應用及其用途
WO2025095751A1 (ko) * 2023-10-30 2025-05-08 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
TW202535865A (zh) 2023-10-31 2025-09-16 美商必治妥美雅史谷比公司 泛素特異性加工蛋白酶1 (usp1) 化合物
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025180502A1 (zh) * 2024-03-01 2025-09-04 上海齐鲁制药研究中心有限公司 一种联合用药物组合物及其用途
KR20250138136A (ko) * 2024-03-12 2025-09-19 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
AU3204895A (en) 1995-02-01 1996-08-21 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
EP0934526B1 (en) 1996-10-08 2003-01-08 U-BISys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US9512125B2 (en) * 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2007149484A2 (en) 2006-06-20 2007-12-27 Dana-Farber Cancer Institute Inhibitors of usp1 deubiquitinating enzyme complex
AU2007325900A1 (en) 2006-10-20 2008-06-05 Dnar, Inc. DNA damage repair inhibitors and methods for treating cancer
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
BRPI0817503B8 (pt) * 2007-10-05 2021-05-25 Sstarbio Pte Ltd derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
CN102014631A (zh) * 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
JPWO2009157196A1 (ja) * 2008-06-25 2011-12-08 武田薬品工業株式会社 アミド化合物
GB0917934D0 (en) * 2009-10-13 2009-11-25 Syngenta Ltd Herbicidal compounds
CA2797719C (en) 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
CA2896731A1 (en) 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
JP2017510628A (ja) * 2014-03-13 2017-04-13 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 縮合ピリミジン系ヒドロキサメート誘導体
KR101766194B1 (ko) * 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
US10189841B2 (en) * 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
BR112021010715A2 (pt) 2018-12-20 2021-11-16 Ksq Therapeutics Inc Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
US20240182481A1 (en) 2021-02-15 2024-06-06 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer

Also Published As

Publication number Publication date
AU2019405925A1 (en) 2021-07-29
SG11202106232TA (en) 2021-07-29
AU2019405925B2 (en) 2025-07-03
US11787813B2 (en) 2023-10-17
JP2022511515A (ja) 2022-01-31
TW202039501A (zh) 2020-11-01
CN113164485A (zh) 2021-07-23
US11485736B2 (en) 2022-11-01
TWI895986B (zh) 2025-09-01
EP3897652A4 (en) 2022-09-14
KR20210105887A (ko) 2021-08-27
JP7662519B2 (ja) 2025-04-15
IL284050A (en) 2021-08-31
IL284050B1 (en) 2025-09-01
KR102912147B1 (ko) 2026-01-13
EP3897652A1 (en) 2021-10-27
US20230203046A1 (en) 2023-06-29
CO2021009078A2 (es) 2021-10-29
BR112021010715A2 (pt) 2021-11-16
MX2021007179A (es) 2021-09-28
JP2024150464A (ja) 2024-10-23
IL284050B2 (en) 2026-01-01
TWI834784B (zh) 2024-03-11
TW202421630A (zh) 2024-06-01
PH12021551402A1 (en) 2023-05-03
CL2021001575A1 (es) 2022-06-03
US20210115049A1 (en) 2021-04-22
WO2020132269A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
CA3122108A1 (en) Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
AU2023202125B2 (en) Pyridazinones and methods of use thereof
CA2966559C (en) Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors
JP6373978B2 (ja) イミダゾピロリジノン誘導体および疾患の処置におけるその使用
JP6430512B2 (ja) リジン特異的デメチラーゼ−１の阻害剤
AU2020204287A1 (en) Inhibitors of lysine specific demethylase-1
AU2015276264B2 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
CA3038280A1 (en) Heteroaryl derivatives as sepiapterin reductase inhibitors
AU2014241152A1 (en) Benzimidazolone derivatives as bromodomain inhibitors
SK13122003A3 (sk) Pyrazolopyrimidíny ako terapeutické prostriedky
KR20170005876A (ko) Ｔａｎｋ-결합 키나제 억제제 화합물
MX2011006997A (es) Compuestos de heteroarilo utiles como inhibidores de cinasa de factor recombinante activado (raf).
WO2021247606A1 (en) Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
AU2020362763A1 (en) Compound having BRD4 inhibitory activity, preparation method therefor and use thereof
MX2013006054A (es) Compuestos de triazolopiridina.
KR20210124961A (ko) 티로신 키나제 억제제, 조성물 및 방법
CA3181209A1 (en) Inhibitors of fibroblast growth factor receptor kinases
AU2019383845B2 (en) Novel tricyclic compound as IRAK4 inhibitor
KR20210100612A (ko) 시클로알칸-1,3-디아민 유도체
RU2833222C2 (ru) Замещенные пиразолопиримидины и замещенные пурины и их применение в качестве ингибиторов убиквитин-специфической процессирующей протеазы 1 (usp1)
HK1230202A1 (en) Inhibitors of lysine specific demethylase-1
HK1230202B (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241209

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250217

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20250512

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250815

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250818

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250818

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250819

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251016

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251016

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251212

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20260325

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260331

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260408

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260408

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260408